Welcome
Support Centre
04 July 2009 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   UKCTG  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
Intramuscular depomedrone in very early inflammatory polyarthritis
ISRCTN ISRCTN69908361
ClinicalTrials.gov identifier
Public title Intramuscular depomedrone in very early inflammatory polyarthritis
Scientific title
Acronym STIVEA
Serial number at source S0671
Study hypothesis That treating patients with very early inflammatory polyarthritis (less than 10 weeks duration) with a three week course of IM steroid will prevent a substantial proportion of cases from evolving into rheumatoid arthritis.
Ethics approval Not provided at time of registration
Study design Randomised controlled trial
Countries of recruitment United Kingdom
Disease/condition/study domain Inflammatory polyarthritis
Participants - inclusion criteria Patients aged 18 years or more with inflammatory polyarthritis with a duration of 4 - 10 weeks.
Participants - exclusion criteria Not provided at time of registration
Anticipated start date 01/06/2003
Anticipated end date 01/06/2006
Status of trial Completed
Patient information material
Target number of participants 346
Interventions Patients will be randomised to receive:
1. Either weekly injections of 80 mg depomedrone (methyl prednisolone) deep into the gluteal muscles for 3 weeks
2. Placebo
Primary outcome measure(s) The need to start second-line drug therapy (e.g. methotrexate, sulphasalazine) by the 6 month assessment.
Secondary outcome measure(s) 1. Whether the patient has satisfied classification criteria for rheumatoid arthritis
2. The presence of radiological erosions in the hands or feet at 12 months
3. The change in physical disability and clinical diagnosis
Sources of funding Arthritis Research Campaign (UK)
Trial website
Publications
Contact name Professor  Deborah  Symmons
  Address ARC Epidemiology Unit
University of Manchester
  City/town Manchester
  Zip/Postcode M13 9PT
  Country United Kingdom
  Tel +44 (0)161 275 5037
  Fax +44 (0)161 275 5043
  Email deborah.symmons@fs1.ser.man.ac.uk
Sponsor Arthritis Research Campaign (ARC) (UK)
  Address Copeman House
St Mary's Court
St Mary's Gate
Chesterfield
  City/town Derbyshire
  Zip/Postcode S41 7TD
  Country United Kingdom
  Email info@arc.org.uk
  Sponsor website: http://www.arc.org.uk
Date applied 05/02/2002
Last edited 28/09/2007
Date ISRCTN assigned 05/02/2002
Submit your trial protocol
Submit to Trials journal
© ISRCTN


BioMed Central